Background: Patients with non-small cell lung cancer (NSCLC) and stable disease (SD) have an unmet clinical need to help guide early treatment adjustments.
Objective: To evaluate the potential of tumor biomarkers to inform on survival outcomes in NSCLC SD patients.
Methods: This post hoc analysis included 480 patients from the IMpower150 study with metastatic NSCLC, treated with chemotherapy, atezolizumab and bevacizumab combinations, who had SD at first CT scan (post-treatment initiation). Patients were stratified into high- and low-risk groups (overall survival [OS] and progression-free survival [PFS] outcomes) based on serum tumor biomarker levels.
Results: The CYFRA 21-1 and CA 125 biomarker combination predicted OS and PFS in patients with SD. Risk of death was ~4-fold higher for the biomarker-stratified high-risk versus low-risk SD patients (hazard ratio [HR] 3.80; 95% confidence interval [CI] 3.02-4.78; p < 0.0001). OS in patients with the low- and high-risk SD was comparable to that in patients with the CT-defined partial response (PR; HR 1.10; 95% CI 0.898-1.34) and progressive disease (PD) (HR 1.05; 95% CI 0.621-1.77), respectively. The findings were similar with PFS, and consistent across treatment arms.
Conclusions: Biomarker testing shows potential for providing prognostic information to help direct treatment in NSCLC patients with SD. Prospective clinical studies are warranted.ClinicalTrials.gov: NCT02366143.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3233/TUB-230001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhanced Analytical Performance in CYFRA 21-1 Detection Using Lateral Flow Assay with Magnetic Bioconjugates: Integration and Comparison of Magnetic and Optical Registration.
Biosensors (Basel)
December 2024
Prokhorov General Physics Institute of the Russian Academy of Sciences, 38 Vavilov Street, 119991 Moscow, Russia.
A novel approach to developing lateral flow assays (LFAs) for the detection of CYFRA 21-1 (cytokeratin 19 fragment, a molecular biomarker for epithelial-origin cancers) is proposed. Magnetic bioconjugates (MBCs) were employed in combination with advanced optical and magnetic tools to optimize assay conditions. The approach integrates such techniques as label-free spectral-phase interferometry, colorimetric detection, and ultrasensitive magnetometry using the magnetic particle quantification (MPQ) technique.
View Article and Find Full Text PDFAssessing the 9G Technology Blood Test for Predicting Lung Cancer in Patients with CT-Detected Lung Nodules: A Multicenter Clinical Trial.
Cancers (Basel)
November 2024
Precision Medicine Lung Cancer Center, Konkuk University Medical Center, Seoul 05029, Republic of Korea.
: Lung nodules detected by chest computed tomography (CT) often require invasive biopsies for definitive diagnosis, leading to unnecessary procedures for benign lesions. A blood-based biomarker test that predicts lung cancer risk in CT-detected nodules could help stratify patients and direct invasive diagnostics toward high-risk individuals. : In this multicenter, single-blinded clinical trial, we evaluated a test measuring plasma levels of p53, anti-p53 autoantibodies, CYFRA 21-1, and anti-CYFRA 21-1 autoantibodies in patients with CT-detected lung nodules.
View Article and Find Full Text PDFDetection of Protein Markers From Blood Samples of Cervical Cancer Patients.
Cureus
October 2024
Microbiology, University of Dhaka, Dhaka, BGD.
Article Synopsis
- The study investigates the role of serum proteins as biomarkers for early detection of HPV-related cervical cancer, focusing on proteins like CEA, SCCA, HMGB1, and CYFRA 21-1.
- Analysis of blood samples from 36 cervical cancer patients revealed that CEA was the most frequently detected protein, highlighting variations based on different HPV types.
- The findings suggest that CEA could serve as a reliable biomarker for cervical cancer, especially in cases linked to HPV-16, which showed the highest response rates among the tested proteins.
Multi-center study on the application potential of Siaα-2,6Gal in early and differential diagnosis of lung cancer.
Clin Chim Acta
January 2025
Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China. Electronic address:
Article Synopsis
- The study investigated the potential of the abnormal glycan structure Siaα-2,6Gal for diagnosing lung cancer early and differentiating it from other conditions.
- Clinical data and serum samples were analyzed from 730 lung cancer patients and 120 healthy individuals, measuring various serum markers including Siaα-2,6Gal and traditional tumor markers.
- Results showed that Siaα-2,6Gal levels were significantly higher in lung cancer patients, especially in early-stage cases, indicating it may serve as a more effective biomarker than traditional tests for diagnosing lung cancer.*
Chemiluminescent FeO@Nickel-Cobalt Double Hydroxide Magnetic Core-Shell Nanomaterial as an Analytical Interface for Label-Free CYFRA21-1 Immunosensing.
Anal Chem
November 2024
Key Laboratory of Precision and Intelligent Chemistry, University of Science and Technology of China, Hefei, Anhui 230026, China.
Cytokeratin 19 fragment (CYFRA21-1) is considered to be a potential marker for the diagnosis and of classification of lung cancer. It is highly desired to develop rapid and highly sensitive label-free chemiluminescence (CL) immunosensors for the detection of CYFRA21-1. In this work, magnetic core-shell nanocomposite FeO@nickel-cobalt double hydroxide (FeO@DH) was used for the first time as a carrier to synthesize N-(4-aminobutyl)-N-ethylisoluminol (ABEI) and gold and silver nanocluster (AuAgNC) bifunctionalized magnetic nanomaterials FeO@DH/AuAgNCs-ABEI.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!